Fortitude Family Office’s Q32 Bio QTTB Stock Holding History

Fortitude Family Office’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-562	Closed	-$927	–	2157
2025 Q1	$927	Hold	562	–	–	﹤0.01%	1028
2024 Q4	$1.93K	Buy	+562	New	+$17.7K	﹤0.01%	1041

Other funds holding QTTB

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fortitude Family Office's QTTB Position: Q2 2025 in Review

Fortitude Family Office sold out of Q32 Bio (QTTB) in Q2 2025, closing a stake of 562 shares — an estimated $927 sold.

Fortitude Family Office first reported a position in QTTB in Q4 2024 and held it in 2 quarters. The position peaked at $1.93K in Q4 2024. 61 funds tracked by Wall St. Rank hold QTTB as of Q2 2025.

Fortitude Family Office reported no remaining Q32 Bio position as of Q2 2025 after selling out during the quarter.
Fortitude Family Office sold 562 Q32 Bio shares in Q2 2025, an estimated $927.
Fortitude Family Office first reported a position in Q32 Bio in Q4 2024 and held it in 2 quarters.
Fortitude Family Office's Q32 Bio position peaked at $1.93K in Q4 2024.
61 funds tracked by Wall St. Rank held Q32 Bio as of Q2 2025.

Based on Fortitude Family Office's 13F filing for Q2 2025, filed 15 Jul 2025.